Status:
UNKNOWN
A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions:
Chronic Hepatitis b
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
This is a phase 1 study in which healthy adult subjects will receive TQA3038 or placebo and will be assessed for safety, tolerability, pharmacokinetics. In the single ascending dose (SAD) part, healt...
Eligibility Criteria
Inclusion
- Male or female age 18～60 years.
- Body mass index (BMI) 19 - 26 kg/m\^2.
Exclusion
- Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation；
- History or evidence of drug or alcohol abuse；
- History of intolerance to SC injection；
Key Trial Info
Start Date :
November 30 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT06085053
Start Date
November 30 2023
End Date
December 1 2025
Last Update
December 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital
Wuhan, Hubei, China, 40030